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(Adapted from Gao et al. 2020. Protein Sci.) 
 
Abstract  
Identification of the molecular networks that facilitated the evolution of multicellular animals from their 
unicellular ancestors is a fundamental problem in evolutionary cellular biology. Choanoflagellates are recognized 
as the closest extant non-metazoan ancestors to animals. These unicellular eukaryotes can adopt a multicellular-
like “rosette” state. Therefore, they are compelling models for the study of early multicellularity. Comparative 
studies revealed that a number of putative human orthologs are present in choanoflagellate genomes, suggesting 
that a subset of these genes were necessary for the emergence of multicellularity. However, previous work is 
largely based on sequence alignments alone, which does not confirm structural nor functional similarity. Here, 
we focus on the PDZ domain, a peptide-binding domain which plays critical roles in myriad cellular signaling 
networks and which underwent a gene family expansion in metazoan lineages. Using a customized sequence 
similarity search algorithm, we identified 178 PDZ domains in the Monosiga brevicollis proteome. This includes 
11 previously unidentified sequences, which we analyzed using Rosetta and homology modeling. To assess 
conservation of protein structure, we solved high resolution crystal structures of representative M. brevicollis 
PDZ domains that are homologous to human GIPC and SHANK1 PDZ domains. To assess functional 
conservation, we calculated binding affinities for mbGIPC, mbSHANK and mbSNX27 PDZ domains from M. 
brevicollis. We find that peptide selectivity is generally conserved between these two disparate organisms. 




The events in molecular evolution that led to the origination of multicellular eukaryotes are preserved in 
the genomes of choanoflagellates, and they are recognized as the closest living relatives to the common ancestor 
of metazoans and unicellular eukaryotes.1,2 Of particular interest in evolutionary cellular biology is the ability of 
choanoflagellates to adopt a primitive multicellular state, known as a rosette.3–5 Comparative studies have 
revealed that several human gene families have clear orthologs in the choanoflagellate clade, and many of these 
orthologous genes are differentially expressed during development of the rosette.6 Furthermore, over 350 gene 
families previously thought to be present only in animal lineages exist in choanoflagellate genomes.6 Therefore, 
there is interest in understanding the molecular underpinnings of signaling pathway proteins in choanoflagellates, 
in order to gain insight into how multicellularity emerged. Investigators have identified a multitude of conserved 
protein structural domains and architectures in the choanoflagellate proteome that are essential to metazoan 
intracellular signaling systems and development. Some examples include the Notch receptor, kinases (e.g., Src 
family kinases, CamKII, etc.), ubiquitin ligases (e.g., Cbl), and PDZ domains, amongst others.2,7–11 Notably, 
although functionally present, mechanisms of regulation can vary dramatically; while the phosphorylation-
dependent regulation of Cbl is conserved in metazoans and choanoflagellates, the allosteric regulation of the SH3-
SH2-Kinase module of Src family kinases is distinct.9,12,13   
Of the shared gene families in metazoans and choanoflagellates, the PDZ domain is particularly interesting 
for a number of reasons. PDZ domains play key functional roles in neuronal signaling, and the intercellular 
 
 
attachments that are formed during rosette development are reminiscent of neuronal synapses.4,14–16 In addition, 
PDZ domains are overrepresented in the genome of choanoflagellate Monosiga brevicollis relative to the 
unicellular eukaryote Saccharomyces pombe.2 Finally, PDZ domains are known to have proliferated in the 
metazoan lineage.16–19 Collectively, these data suggest that PDZ domains played an important role in the evolution 
of multicellularity and that further characterization of PDZ domains in choanoflagellates may yield insights into 
molecular mechanisms that facilitated primitive multicellular development.  PDZ domains were named after the 
first PDZ domain-containing proteins that were identified (PSD-95, Dlg1, and ZO-1).20–24 These initially 
discovered PDZ domains all contain a “GLGF” amino acid sequence. This shared sequence, referred to as the 
GLGF-loop, or the carboxylate-binding loop, comprises a key component of the canonical PDZ domain structure. 
The well-conserved PDZ domain structure dictates its function in mediating protein-protein interactions. 
Specifically, the amide nitrogen atoms in the backbone of the GLGF-loop directly interact with the carboxylate 
atoms of the extreme C-terminus of a protein ligand.25,26 PDZ domains are approximately 80-100 residues in 
length, and comparative analysis of hundreds of PDZ structures in the Protein Data Bank reveals a conserved 
structural fold, consisting of a core antiparallel b-sheet and 1-2 a-helices (Figure 1).26–32   
PDZ domains are scaffolding domains that bind target 
proteins. In some instances, this facilitates localization of target 
proteins within close proximity of auxiliary enzymatic domains on 
the same polypeptide. In other instances, PDZ domain scaffolding 
activity functions to mediate protein trafficking, and impacts 
cellular signaling pathways. These PDZ domain interactions can 
be modulated by other protein-protein interaction domains on the 
same polypeptide, or in trans, by other proteins in larger 
macromolecular complexes.26,33,34 An example of the scaffolding 
function of PDZ domains is the postsynaptic density of neurons, 
where multiple receptor signaling networks are brought into close 
physical proximity due to a number of PDZ domain-mediated 
interactions.35 As mentioned previously, an expansion of the 
number of PDZ domain-containing genes coincided with the emergence of animal multicellularity.17 This 
suggests that PDZ domains played a critical role in the evolution of multicellular animals. The human proteome 
contains 272 PDZ domains in a variety of protein architectures, but all PDZ domains share the same basic 
biochemical function of scaffolding protein-protein interactions.  
Considering the importance of PDZ domains in a number of cellular processes, significant effort has been 
invested in characterizing their peptide-binding selectivity. These domains bind to short sequences in target 
proteins, often interacting with only 6 amino acid residues. In fact, the motifs of classically determined PDZ 
binding classes are dependent on only two residues, the extreme C-terminal residue, termed P0 and two residues 
adjacent, or P-2.26 For example, Class I PDZ domains recognize the motif X-S/T-X- f at the C-terminus of target 
proteins (where X=any amino acid and f=any hydrophobic amino acid).26 Work in the last 10+ years using high 
throughput techniques, e.g., phage display, peptide array, or the hold-up assay, has shifted this classical view of 
PDZ domain binding to appreciate the importance of binding interactions at non-motif residues in the peptide-
binding cleft.36–38 In addition, a number of elegant studies using directed evolution, or other protein engineering 
techniques, have successfully identified structural elements that determine PDZ selectivity -- often through only 
a small number of amino acid substitutions or post-translational modifications.39–43   
The elucidation of PDZ binding selectivity has enabled investigators to trace the evolution of PDZ 
specificity throughout the tree of life, including in bacteria, yeast, and plants.18,42,44 However, what remains to be 
Figure 1. Conserved fold of PDZ domain 
structures. The human PDZ homologues of the 
M. brevicollis PDZ domains studied in this paper 
are shown in cartoon representation, colored by 
conserved secondary structure elements, as 




determined is whether or not the selectivity determinants in PDZ domains related by evolution are also conserved, 
despite different signaling pathways, e.g., in uni- versus multicellular organisms, or those with and without a 
nervous system. Previous work looking at the evolution of PDZ domains found that six amino acid positions 
determine lineage relationships amongst 40,000 PDZ domains in 40 proteomes and that four of these positions 
are in direct contact with non-motif peptide residues (P-1 and P-3).16 This result suggests that homologous proteins 
will share conserved residues in the peptide-binding cleft, including those amino acids that directly interact with 
residues beyond the P0 and P-2 motif positions.   
In order to investigate these questions on a molecular level, we crystallized and solved four total structures 
of two PDZ domains from the choanoflagellate, Monosiga brevicollis, including homologues of PDZ domains 
from the human proteins GIPC1 and SHANK1 (Figure 1). We also investigated the binding affinities of a 
homologue of human SNX27 (Figure 1). These proteins are important in postsynaptic signaling and well-
conserved in M. brevicollis, despite over 200 million years of evolution between the last common ancestor of 
humans and choanoflagellates -- and the emergence of neurons.35,45–47 Structural and binding affinity analyses 
confirm that the residues in the peptide-binding clefts are generally conserved in these proteins. Previous studies 
investigated the molecular basis of evolution, expansion, and rewiring in PDZ domain networks; however, here 
we find that for closely related PDZ domains, selectivity determinants for all residues in the binding cleft are 
generally conserved in evolution, despite a lack of conservation in shared target proteins.48,49 
 
Results  
Structural and biochemical characterization of mbGIPC PDZ  
  To determine if residues that directly interact with the ligand are conserved, including all of those within 
the peptide-binding cleft of Class I PDZ domains, we set out to characterize a number of PDZ domains from 
Monosiga brevicollis with clear homology to human PDZ proteins. We first chose to investigate the homolog of 
the human GAIP interacting protein, C terminus, or GIPC.50 GIPC was first identified as an interactor of the G-
alpha interacting protein (GAIP), but was quickly shown to also interact directly with G-protein coupled receptors, 
as well as dopamine and NMDA receptors in excitatory synapses of the central nervous system.47,50–52 Thus, GIPC 
is important for both G-protein coupled receptor (GPCR) and neuronal signaling in human cells, and additional 
studies have shown that it broadly regulates vesicular trafficking of many transmembrane receptors via 
interactions with myosin VI.30  
The presence of a GIPC homolog in M. brevicollis is consistent with the identification of adhesion GPCRs 
in choanoflagellates.53,54 Overall, full length GIPC proteins from human and M. brevicollis (UniProt ID: 
A9VCZ3_MONBE, termed mbGIPC) share 56% sequence identity over 79% of the protein. The human GIPC 
protein is a Class I PDZ binding domain, as defined above. Recognition of the P-2 Ser/Thr residue is facilitated 
by hydrogen bond formation with a conserved histidine in the first position of the conserved αB helix, termed 
αB-1.26 The human and choanoflagellate GIPC PDZ domains are 58% identical over 88% of the PDZ sequence, 
as defined by UniProt boundaries, including shared carboxylate-binding loop sequences of ALGL and 
conservation of the Class I-defining histidine in the αB-1 position (Figure S1A).  
We expressed and purified mbGIPC PDZ using previously described methods, and as described in more 
detail in the Materials and Methods.38,55 Briefly, we used recombinant expression in Escherichia coli cells, 
followed by affinity and size exclusion chromatography to produce purified mbGIPC PDZ protein. With protein 
in hand, we crystallized and solved the structure of mbGIPC PDZ to a high resolution of 1.2 Å, as described in 
the Materials and Methods and Supplementary Information. Overall, this structure is consistent with the conserved 
PDZ fold, characterized by the central five-stranded antiparallel b-sheet (bA-E) (Figure 1). As mentioned above, 
while many PDZ domains contain two a-helices (aA-B), it appears that aA is slightly strained and therefore not 
 
 
fully formed in the mbGIPC structure, a characteristic 
that is also true of the human GIPC PDZ domain (PDB 
IDs: 5V6B and 5V6T).30 The peptide ligand forms an 
additional strand of the central b-sheet (Figure 2A). 
Data collection and refinement statistics are in Table 
S1A. 
Although we had added a peptide matching the 
GAIP sequence, a high affinity human GIPC PDZ 
target, during crystallization, we were surprised to see 
that our crystal structure lacked the bound peptide. 
Instead mbGIPC was interacting with the C-terminal 
tail of a molecule related by symmetry (Figure S1B). 
This is a common mode of co-crystallization for PDZ 
domains and ligands, e.g., in the NHERF1 PDZ bound 
to the cystic fibrosis transmembrane conductance 
regulator (CFTR) structure, as well as others.29,56 The 
NHERF1 PDZ1-CFTR example is distinct from our 
structure, however, in that the C-terminus of mbGIPC 
is not a Class I PDZ-satisfying motif (sequence: 
KSFDEI). In our structure, which we will refer to as 
mbGIPCSFDEI, we see that the P0 Ile is accommodated 
by a hydrophobic pocket, as expected in Class I PDZ 
interactions. However, the conserved αB-1 H157 
residue is forming hydrogen bonds with the Asp in the 
P-2 position (distance: 2.6 Å), as well as the Ser in the 
P-4 position (2.8 Å) (Figure S1C).   
In order to determine if this interaction is a 
crystal artifact, we created a truncated mutant, 
mbGIPCtrunc, lacking the final 7 residues of our original 
construct (or K181D), and calculated binding affinities 
for human GIPC targets using fluorescence 
polarization. We first measured the binding affinity of 
mbGIPCtrunc for a decameric fluorescent reporter 
peptide matching the sequence of GAIP (F*-
QGPSQSSSEA, where F* = FITC or fluorescein 
isothiocyanate), calculating a KD = 0.29 ± 0.02 µM in a 
quadruplicate experiment (Figure S1D). Next, we determined the affinities of a number of human GIPC PDZ 
targets using competition experiments, including decameric peptides of the C-termini of GAIP (QGPSQSSSEA), 
tyrosinase-related protein 1 (TYRP1, sequence: KLQNPNQSVV), and the b-1 adrenergic receptor (B1AR, 
sequence: RPGFASESKV) (Table 1, Figure 2B). Experimental protocols were based on previously described 
methods and are described in more detail in the Materials and Methods.38,55,57,58   
The binding affinities of mbGIPCtrunc PDZ for human GIPC PDZ targets suggest a large degree of 
conservation in selectivity determinants. Specifically, the affinity of mbGIPC PDZ for GAIP is 0.23 µM, despite 
a BLASTP search revealing no obvious GAIP homolog in M. brevicollis.59 This result also suggests a minimal 
Figure 2. The crystal structure of the mbGIPC PDZ domain. (A) 
The interaction of mbGIPC (gray) with the C-terminal tail of a 
molecule related by symmetry (green), backbone atoms shown in 
stick, reveals a canonical PDZ-peptide interaction where the 
peptide forms an additional strand of an antiparallel b-sheet. 
Distances are labeled. (B) Average fluorescence polarization 
displacement isotherms are shown for mbGIPCtrunc PDZ. 
Titration curves correspond to the following peptides: GAIP 
(circles), B1AR (squares), TYRP1 (diamonds), and a decameric 
peptide matching the C-terminal residues of the construct, ending 
in “SFDEI” (triangles). Error bars indicate the standard deviation 
from the mean for triplicate experiments. (C) Alignment of 
mbGIPC PDZ domains with three separate C-terminal tail 
sequences (gray ribbon, RMSD = 0.21 Å for ~350 main chain 
atoms), with tail sequences as sticks and colored as labeled. (D) 
The conservation between mbGIPC (gray cartoon, with cyan side 
chain residues as sticks; peptide is in cyan ribbon) and human 
GIPC (PDB ID: 5V6B, with Plexin-D1 C-terminal peptide from 
5V6T (hot pink ribbon); gray cartoon with hot pink side chain 
residues as sticks). Residues in the peptide-binding cleft are 




effect of the fluorescein moiety in binding. The binding 
affinities for TYRP1 and B1AR are ~10 and 20x worse, 
respectively (Figure 2B). These values are still relatively 
high to average affinity as compared to typical PDZ 
domain interactions, which can range from the nanomolar 
to hundreds of micromolar range, but are centered around 
1-30 µM (11, 48, 50). Neither TYRP1 nor B1AR have 
clear homologues in M. brevicollis, according to 
BLASTP.59 Notably, a competition experiment with a decameric peptide matching the C-terminal sequence of 
our original construct (“SFDEI” sequence: VEPKKSFDEI) revealed little to no binding, defined here as a Ki > 
1000 µM (Table 1, Figure 2B). Thus, we concluded that the binding interaction in our original structure was a 
crystal artifact.   In order to investigate the stereochemistry of a peptide binding interaction with mbGIPC that is 
not an artifact of crystallization, we mutated the final 5 residues of our original construct to those matching B1AR 
(mbGIPCB1AR; C-terminal sequence: SESKV), GAIP (mbGIPCGAIP; SSSEA), and TYRP1 (mbGIPCTYRP1; 
NQSVV) (Table S1A). Previous work from ourselves and others suggests that the P-5 position is an important 
selectivity determinant in some PDZ domains.37,38 However, we chose to keep this residue a lysine in our new 
constructs, due to crystal lattice contacts made by the lysine side chain, suggesting it may be important for 
crystallization (Figure S1E).   
All 3 complexes successfully crystallized in the same space group as mbGIPCSFDEI and we determined 
crystal structures of mbGIPCB1AR and mbGIPCGAIP. The overall conformations of these structures to each other, 
as well as to the mbGIPCSFDEI structure, were very similar, with pairwise structural alignment RMSD values £ 
0.21 Å for ~350 main chain atoms (Figure 2C). We were unable to fully refine the mbGIPCTYRP1 structure despite 
a successful molecular replacement solution, due to anisotropic data and relatively low resolution, compared to 
the others. Partial refinement (Rwork/Rfree = 24.3/28.9) shows clear peptide-specific density, confirming that this 
sequence interacts with mbGIPC in a manner that is consistent with PDZ domain peptide binding (Figure S1F). 
However, our structural analyses of the mbGIPC and human GIPC PDZ domains will be limited to the 
mbGIPCB1AR and mbGIPCGAIP structures. 
Our mbGIPC structures share high structural similarity with the human GIPC PDZ domain. Structural 
alignment of main chain atoms between the mbGIPCB1AR and hGIPC PDZ domain (PDB ID: 5V6T) is 0.607 Å 
over 299 main chain atoms. This human GIPC PDZ structure was crystallized with the intracellular region of 
Plexin-D1 (C-terminal sequence: CYSEA) and the structures confirm that the peptide binding clefts of mbGIPC 
and human GIPC are very well conserved, with only two conservative substitutions (using human GIPC 
numbering): T148S and R159K (Figure 2D). We were unable to purify soluble human GIPC PDZ in our lab, 
despite testing multiple constructs (including using a SUMO-tag), but our data strongly suggests that the binding 
affinities would be similar between these domains.  
 
Structure Characterization of mbSHANK1 PDZ  
We previously compared binding affinities for another M. brevicollis PDZ domain, that of mbSHANK1 
(UniProt ID: A9V7E4_MONBE), a protein that is homologous to human SHANK1 (Figure S2A).55 In this work, 
we also created a homology model of mbSHANK1 PDZ using SwissModel and predicted stereochemical 
differences in the peptide binding pockets between these two proteins, specifically in those residues that interact 
with the P-3 position.55 Here, we expand that investigation by presenting the crystal structure of mbSHANK1 PDZ 
(Figure 3A, Table S1B).  
 
 
The protein mbSHANK1 PDZ was 
expressed and purified as previously described.55 
Crystallization of this protein in complex with a 
fluoresceinated peptide matching the C-terminus of 
GIRK3 (F*-GIRK3, sequence: F*-LPPPESESKV) 
is described in the Materials and Methods and 
Supporting Information. We collected data to a high 
resolution of ~2.2 Å, however phasing by molecular 
replacement and structure refinement proved 
challenging. We employed an iterative Rosetta 
modeling approach coupled with Phenix in order to 
determine a molecular replacement solution with 
high confidence, as described in detail in the 
Supplementary Information.60–63 Our refinement 
difficulties were due to a large degree of anisotropy 
in the diffraction data. Specifically, the high-
resolution limit along the a* and b* directions (2.2 
Å) was substantially higher than that along the c* 
direction (3.4 Å). We were ultimately able to refine 
this model by truncating and scaling the reflections 
file appropriately, using the UCLA-DOE 
Diffraction Anisotropy Server.64 Crystallization 
attempts with a fluorescent b-PIX peptide 
(sequence: F*-NDPAWDETNL) were 
unsuccessful, despite binding mbSHANK1 PDZ 
with much higher affinity (KD = 7.3 µM for 
mbSHANK1 PDZ, and 5.1 µM for SHANK1 PDZ), 
as previously reported (Table 2).55 For comparison, 
previous attempts to get KD values of mbSHANK1 
and human SHANK1 PDZ domains with the F*-
GIRK3 peptide were incomplete, with estimates of 
affinities >1000 µM for each (data not shown). We 
were also unable to grow crystals of mbSHANK1 in the apo form or following incubation with non-fluorescent 
versions of either the b-PIX or GIRK3 peptides.  
The crystal structure of mbSHANK1 bound to F*- GIRK3 is structurally very similar to our previously 
determined homology model.55 The overall RMSD of these two structures is 0.668 Å over 276 main chain atoms, 
with the largest discrepancy occurring in the flexible bB-bC loop (Figure 3A). In our structure, we see non-
covalent interactions between T471 and the side chains of the P-4 Ser and P-5 Glu residues, as well as the P-5 Glu 
carbonyl, which may have helped to stabilize the bB-bC loop for crystallization and may explain why this 
complex crystallized despite a relatively low binding affinity, although six residues of the loop are disordered in 
our structure (Figures 3B-C). In addition, we see electrostatic interactions between D488 and the P-1 Lys, as well 
as H517 and R518 with the P-2 Ser (Figure 3C). 
In our previous work and based on our mbSHANK1 homology model, we hypothesized that the modest 
increase in affinity for b-PIX by mbSHANK1 PDZ (Ki = 13 µM versus 20 µM for human SHANK1 PDZ) was 
Figure 3. The crystal structure of the mbSHANK1 PDZ domain. (A) 
The mbSHANK1structure (blue cartoon, peptide in stick 
representation) is similar to a previously reported homology model 
(gray cartoon), RMSD = 0.668 Å over 276 main chain atoms.55 The 
black arrows highlight the differences in the flexible bB-bC loop. All 
sticks are colored by heteroatom (O=red, N=blue) and the peptide 
positions are labeled. (B-C) The interactions of the mbSHANK1 
PDZ domain (gray cartoon, with side chains as sticks) with the F*-
GIRK3 peptide (blue sticks, interchangeably referred to as “GIRK3” 
peptide, since the fluorescein moiety is unresolved in the crystal 
structure) is characteristic of PDZ-peptide interactions. 
Measurements between interacting residues in the peptide-binding 
cleft are labeled. The GIRK3 peptide is labeled, and the sequence 
included in the figures is in (B). There is an additional peptide residue 
resolved in the crystal structure, the P-6 Pro, but it does not make 
interactions with mbSHANK1 PDZ. (D) Phylogenetic tree showing 
the relationship of a number of SHANK and SNX27 PDZ domain 
sequences from 11 organisms. SNX27 sequences are colored red. 
The mbSHANK1 and mbSNX27 sequences sit at the branch point of 
the other SHANK and SNX27 sequences. 
 
 
due to an additional arginine residue that 
was located near the P-3 position, and, we 
figured, positioned to interact directly with 
the P-3 Glu.55 Interestingly, our 
experimental structure reveals that neither 
of the arginine residues in the vicinity are 
interacting with the P-3 Glu of GIRK3. 
However, we do see that the sequence and 
length of the bB-bC loop, which directly 
interacts with the peptide P-4 Ser and P-5 
Glu residues in our structure, varies quite 
dramatically: the residues of the 11-residue loop for mbSHANK1 PDZ are not conserved at all with those of the 
18-residue loop of human SHANK1 PDZ. It is unclear how these loops may differentially interact with the P-4 
Asp and P-5 Trp of b-PIX, but otherwise, the crystal structure confirms that the peptide-binding clefts are generally 
conserved.55   
When we ran our initial BLASTP search for SHANK1 PDZ homologues in M. brevicollis, the top two 
sequence hits were relatively close in sequence identity: A9V7E4_MONBE, with 34% sequence identity over 93 
residues, as well as A9URU5_MONBE, with 36% sequence identity over 89 residues (domain boundaries for 
human SHANK1 PDZ (residues 663-757) as defined by UniProt). Sequence alignments using the full-length 
A9V7E4_MONBE protein and the human proteome confirmed its homology to the SHANK protein family, 
specifically due to the additional presence of ankyrin repeat domains, as well as SH3 and SAM domains.45,65 
Sequence alignments using the full-length A9URU5_MONBE sequence and human proteome suggested that it is 
a homologue of sorting nexin-27 (SNX27), with 25% sequence identity over 96% of the protein. Therefore, we 
will refer to A9URU5_MONBE as mbSNX27. 
We were interested in the relationship between the PDZ domain sequences in these four proteins due to 
the similar sequence similarities between mbSHANK1 and mbSNX27 PDZ domains and human SHANK1 PDZ. 
Therefore, we conducted a phylogenetic tree analysis of 10 PDZ sequences for SHANK1 or SNX27 homologues 
in a variety of organisms, as well as the PDZ domain sequences of mbSHANK1 and mbSNX27 (Figure 3D). 
Because we see that mbSHANK1 and mbSNX27 sit at the branch point between the SNX27 and SHANK1 
sequences, we expressed and purified SNX27 and mbSNX27 PDZ domains, as described in the Materials and 
Methods, and compared binding affinities for all four domains using fluorescence polarization to 6 decameric 
peptides matching the C-termini of: b-PIX, GIRK3, and mGluR1, as well as A9UP44_MONBE, 
A9UXE1_MONBE, and A9V724_MONBE, which were previously identified as potential M. brevicollis targets 
of mbSHANK1 (Figures S2B-D, Table 2).55   
Our results reveal that overall, peptides which bind human SNX27 PDZ with relatively high affinity also 
bind mbSNX27 PDZ very strongly (Table 2). As previously reported, this is also true with human SHANK1 and 
mbSHANK1 PDZ domains (Table 2).55 However, in all cases, the exact order of highest to lowest affinity 
peptides is distinct, perhaps reflective of single substitutions in the peptide binding cleft. We described the 
differences for SHANK1 and mbSHANK1 PDZ domains above and previously.55 A homology model of 
mbSNX27 PDZ, using SNX27 PDZ as a template (PDB ID: 6SAK) contains the following substitutions at 
residues that may interact with the peptide (numbering based on SNX27): R58K, V61T, A83H, and R122I 
(Figure S2E). In addition, while the mGluR1 peptide binds the human PDZ domains with moderate affinity, it 
shows no measurable affinity for either of the M. brevicollis PDZ domains. Taken together, the resulting binding 
affinities are consistent with our central hypothesis that the target selectivity of PDZ lineages were set early in 
Table 2. Binding affinities of SHANK1, SNX27, mbSHANK1 and 
mbSNX27 PDZ domains. 
SHANK1 and mbSHANK1 PDZ domain measurements are previously 
published, with the exception of the GIRK3 peptide.55  
 
 
evolution, even in proteins that appear to be closely related to each other, e.g., SHANK1 and SNX27 PDZ 
domains, based on overall sequence identity. 
 
Concluding Remarks  
Structural comparison of the peptide-binding clefts and peptide interactions of homologous domains from 
organisms related by hundreds of millions of years of evolution has the potential to provide insight into signaling 
networks in those species. Here, we chose to use structural biology and biochemistry to investigate two PDZ 
domain-containing proteins that are important in human neuronal signaling in a species of choanoflagellates, our 
closest non-metazoan ancestors. Many of the human targets of SHANK1 and GIPC1 are either not conserved in 
choanoflagellates or do not contain PDZ binding sequences.55 However, we find that the peptide binding-cleft 
residues and binding affinities for human and/or choanoflagellate peptides are generally conserved in these related 
domains. Specifically, we see strong binding affinity correlations in SHANK1 and mbSHANK1 versus SNX27 
and mbSNX27 PDZ domains, despite binding cleft substitutions in both cases. 
Our structures of two unique M. brevicollis PDZ domains provide the first structural determination of 
choanoflagellate PDZ domains to our knowledge. Furthermore, our comparisons with known human PDZ domain 
structures, as well as homology and Rosetta modeling confirm that because the PDZ domain fold is so well 
conserved, it is possible to get an initial idea of a PDZ domain structure without experimental structure 
determination. We hypothesize that these types of analyses can be applied to PDZ domains from multiple 
organisms related by evolution.   
Protein-protein interactions that involve PDZ domains act as critical nodes for signaling and trafficking 
pathways in a cell. It is clear that this is true in differentiated cells, such as those in complex multicellular 
organisms, as well as in single-celled organisms. Deciphering the PDZ-mediated interactions in choanoflagellates 
may elucidate important characteristics of the selectivity determinants and the evolution of this important peptide-
binding domain. Furthermore, there are a number of proteins and protein architectures that contain PDZ domains 
in choanoflagellates that are not conserved in humans. Future work could investigate how these proteins, for 
example A9VDV9 mentioned above, act in signaling pathways in M. brevicollis and how this provides insight 
into the transition from uni- to multicellular life on Earth. Taken together, we suggest that investigating the 
structure-function relationship for individual domains in both uni- and multicellular organisms is an important 
component in building a holistic understanding of the signaling networks of an organism and in understanding 
the origin of multicellularity.  
 
Materials and Methods  
Protein Expression and Purification. Expression and purification of all human and M. brevicollis PDZ domains 
followed a similar protocol as previously reported for mbSHANK1 PDZ.55 Histagged versions of the PDZ 
domains were inserted into the pET28a+ vector (GenScript) and expressed in Escherichia coli BL21 (DE3) cells. 
Cells were lysed using sonication and immobilized metal-affinity chromatography (5 mL HisTrap (GE 
Healthcare)) was used to purify proteins from the clarified supernatant. The wash buffer used was: 25 mM 
imidazole pH 8.5, 25 mM Tris pH 8.5, 25 mM NaCl, 10% (v/v) glycerol, and 0.25 mM TCEP, and elution buffer 
was: 400 mM imidazole pH 8.5, 25 mM Tris pH 8.5, 50 mM NaCl, 10% (v/v) glycerol, and 0.5 mM TCEP. With 
the exception of human SHANK1 and SNX27 and mbSNX27 PDZ domains, the protein was then dialyzed in 
dialysis buffer (same as gel filtration buffer described below), and incubated with PreScission protease to cleave 
off the His-tag. The cleaved protein was then purified using a second nickel column with the wash and elution 
buffers described above. All proteins were further purified on a Superdex S75 column, using gel filtration buffer 
[25 mM Tris pH 8.5, 125 mM NaCl, 10% (w/v) glycerol, 0.5 mM TCEP]. Proteins were concentrated using 
 
 
Amicon centrifugal concentrators (3 MWCO). Concentrated proteins used in fluorescence polarization assays 
were flash frozen in liquid nitrogen for storage at -80°C. Proteins used for crystallization were stored at 4°C.  
Proteins were quantitated with the A280 and the experimental extinction coefficient values of: 1490 cm-
1*M-1 for all mbGIPC PDZ domains (including mbGIPCSFDEI, mbGIPCtrunc, mbGIPCB1AR, mbGIPCGAIP, and 
mbGIPCTYRP1), 8480 cm-1*M-1 for SHANK1 PDZ, 11000 cm-1*M-1 for mbSHANK1, 9970 cm-1*M-1 for 
mbSNX27 PDZ and 2980 cm-1*M-1 for SNX27 PDZ. 
 
Crystallization, Data Collection, and Structure Determination. Prior to crystallization, all PDZ domains were 
dialyzed into a crystallization buffer [25 mM NaCl, 10 mM Hepes pH 7.4] for 2-4 hours. The protein 
concentrations used for crystallization were as follows: mbSHANK1 (6 mg/mL), mbGIPCSFDEI (23.4 mg/mL), 
mbGIPCB1AR (17 mg/mL), mbGIPCGAIP (22.8 mg/mL), and mbGIPCTYRP1 (27.3 mg/mL). Peptide was added at a 
final concentration of 1 mM and incubated with protein for 1-hour prior to crystallization for F*-
GIRK3:mbSHANK1 PDZ. All initial crystallization conditions were identified using the PEG/Ion screen 
(Hampton Research). The crystallization conditions of crystals used for data collection were: mbGIPCSFDEI [100 
mM ammonium tartrate dibasic pH 7.0, 12% (w/v) PEG 3350], mbGIPCB1AR [200 mM sodium malonate pH 7.0, 
20% (w/v) PEG 3350], mbGIPCGAIP [4% (v/v) Tacsimate pH 4.0, 12% (w/v) PEG 3350], mbGIPCTYRP1 [100 mM 
DL-Malic acid pH 7.0, 12% (w/v) PEG 3350], and mbSHANK1 [250 mM NaCl, 100 mM Bis-Tris pH 5.5, 32% 
(w/v) PEG 3350].   
For data collection, crystals were transferred into cryoprotectant buffer.  For mbSHANK1, this was well 
solution plus 20% (w/v) glycerol. For other proteins, 15% (w/v) glycerol was added directly to the respective 
PEG/Ion screen solution. The crystals were flash-cooled by plunging into liquid nitrogen. Data was collected at 
the Advanced Light Source (ALS) at the Lawrence Berkeley National Laboratory (LBNL) on beamline 5.0.1, at 
l=0.977410 Å over 360°, with Df=0.25° frames and an exposure time of 0.5 s per frame. Data were processed 
using the XDS package (Table S1).83–85 Molecular replacement was performed using Phenix with the following 
search models: mbGIPC (PDB ID: 5V6B, human GIPC) and mbSHANK1 (de novo structural model using the 
Robetta server and Rosetta optimization as described in the Supplemental Information).60,86,87 Refinement was 
performed using Phenix, manual refinement was done using Coot, and model geometry was assessed using 
Molprobity and the PDB validation server.60,86,89–93 All crystal data and refinement statistics are in Table S1. 
Additional details regarding the structure determination of mbSHANK1 is in the Supplemental Information. PDB 
accession codes for the structures presented here are: 6X1X (mbGIPCSFDEI), 6X20 (mbGIPCB1AR), 6X22 
(mbGIPCGAIP) and 6X23 (mbSHANK). 
 
Binding assays by fluorescence polarization. Fluorescence polarization assays were performed as previously 
described.25,38,55,58 Replicate experiments were performed to determine the KD values of mbGIPCtrunc PDZ (N=4) 
for the fluorescence peptide, F*-GAIP (FITC-QGPSQSSSEA), and SNX27 PDZ (N=3) for the fluorescent 
peptides, F*-b-PIX (FITC-NDPAWDETNL) and F*-GIRK3 (FITC-LPPPESESKV) (Figures S1D, S2B). For 
mbGIPCtrunc PDZ we determined a KD value of 0.29 ± 0.02 µM for F*-GAIP. For SNX27 we determined a KD 
value of 0.022 ± 0.007 µM for F*-b-PIX and 0.327 ± 0.135 µM for F*-GIRK3. Limited yield of purified 
mbSNX27 resulted in the inability to calculate KD values for that protein, thus, we reported IC50 values for our 
unlabeled peptides (Figure S2D, Table 2). 
Competition experiments: The final protein concentrations for Ki experiments were equal to: 0.6 µM for 
mbGIPC PDZ, 0.05 µM for SNX27 PDZ, and 5 µM for mbSNX27 PDZ. For SHANK1 and mbSHANK1 PDZ 
Ki experiments with the GIRK3 peptide, we used 10 µM protein (based on previously-determined KD values of 
 
 
7.3 µM for mbSHANK1 PDZ, and 5.1 µM for SHANK1 PDZ).55 Competition experiments were performed in 
triplicate, using the following reporter peptides at 30 nM final concentration: mbGIPC (F*-GAIP), SNX27 (F*-
b-PIX) and mbSNX27 (F*-b-PIX). Binding affinities for Ki experiments were determined using SOLVER and 
IC50 values using Kaleidagraph, as previously described (Figures 2B, S2C-D).38,57,58 
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Figure S1. Crystal contacts in mbGIPCSFDEI structure and electron density for peptide in mbGIPCTYRP1. (A) 
Sequence alignment of human GIPC and mbGIPC PDZ domains. (B) The spatial relationship between mbGIPC (green 
cartoon) PDZ and a molecule related by symmetry (gray cartoon, mbGIPC’) is shown. The last 5 residues of the 
mbGIPC’ C-terminal tail (sequence SFDEI) are shown in gray stick. (C) The binding of mbGIPC (green cartoon, H157 
side chain in stick representation) to the C-terminal tail of mbGIPC’ (gray sticks and labeled) is unconventional and a 
crystal artifact. (D) The average fluorescence polarization isotherm is shown for mbGIPCtrunc PDZ and the F*-GAIP 
peptide (at 30 nM), including the standard deviation for each data point. This experiment was performed in quadruplicate 
and the calculated KD = 0.29 ± 0.02 μM. (E) The K182 residue in mbGIPCSFDEI PDZ (green sticks) makes crystal 
lattice contacts with the main chain carbonyl atoms of R134 and V135 in a molecule related by symmetry, mbGIPC’ 
(gray sticks). For this reason, we chose to keep a lysine in this position in our other mbGIPC constructs (mbGIPCB1AR, 
mbGIPCGAIP, and mbGIPCTYRP1). (F) Final refinement of mbGIPCTYRP1 proved challenging, so we did not deposit 
this structure in the Protein Data Bank. However, there is clear electron density for the C-terminal sequence, NQSVV 
(2Fo-FC map in blue mesh and contoured at 1s), and it is consistent with mbGIPC binding to the other C-terminal 
sequences (GAIP and B1AR). Here, mbGIPC is in gray cartoon with side chain sticks in gray. The TYRP1 sequence is 





Figure S2. Structural and biochemical characterization of mbSNX27. (A) Sequence alignment of human SHANK1 and mbSHANK1 
PDZ domains. Secondary structure elements are labeled by arrows (b-strands) and wavy lines (a-helices). (B) Example fluorescence 
polarization isotherms are shown for SNX27 PDZ and the F*-b-PIX (black squares) and F*-GIRK3 peptides (black circles, both 
reporter peptides at 30 nM). (C-D) Average fluorescence polarization displacement isotherms are shown for SNX27 PDZ (C) and 
mbSNX27 PDZ (D). Titration curves are shown for the following peptides: b-PIX (circles), GIRK3 (squares), and mGluR1 
(diamonds), or choanoflagellate proteins A9UP44 (triangles), A9UXE1 (upside-down triangles), and A9V7Z4 (gray circles). Error 
bars indicate standard deviation from the mean for triplicate experiments. The reporter peptide used in both experiments was F*-b-
PIX. (E) The conservation between mbSNX27 (gold cartoon, with side chain residues as sticks) and human SNX27 (PDB ID: 6SAK, 
gray cartoon with side chain residues as sticks) is shown. The peptide (GIRK3 sequence: ESESKV) is from an additional human 
SNX27 structure (3QE1) and is shown as gray ribbon and labeled. The RMSD value between the human SNX27 structures is 0.377 
Å over 302 main chain atoms. The mbSNX27 PDZ structure was made using SwissModel with 6SAK as a template. Residues in the 

























Part 2: Structural and binding studies of Class A sortase of Streptococcus agalaticae 
Abstract (adapted from Piper et al. In review. JBC.) 
Gram-positive bacteria contain sortase enzymes on their cell surfaces that catalyze transpeptidation 
reactions critical for proper cellular function. In vitro, sortases are used in sortase-mediated ligation (SML) 
reactions for a variety of protein engineering applications. Historically, sortase A from Staphylococcus aureus 
(saSrtA) has been the enzyme of choice for SML reactions. However, the stringent specificity of saSrtA for the 
sequence motif LPXTG limits its uses. Here we investigate the contribution of this b7- b8 loop, located between 
the catalytic cysteine and arginine residues and immediately adjacent to the target binding cleft, by designing and 
testing chimeric sortase enzymes. Our chimeras utilize natural sequence variation of Class A sortases from four 
species engineered into the SrtA sequence from Streptococcus agalaticae (sagSrtA). We crystallize and solve the 
first known full-length structure of sagSrtA and are working on solving a sagSrtA chimera and peptide-bound 
structures. These studies provide the foundation for a deeper understanding of sortase target selectivity and can 
expand the sortase toolbox for future SML applications.  
Introduction (adapted from Piper et al. In review. JBC.) 
 
Sortases are cysteine transpeptidase enzymes 
that gram-positive bacteria use to covalently attach 
proteins to their cell wall for various functions, 
including to assemble pili or display virulence 
factors.1–3 There are 6 recognized classes of sortase 
enzymes (classes A-F), with in vivo roles ranging 
from general purpose or “housekeeping” functions 
(classes A and E), to more specific roles such as the 
construction of the bacterial pilus (Class C).1,4 These 
enzymes recognize a cell wall sorting signal (CWSS) 
on the outer membrane of gram-positive bacteria.1,5 
For Class A sortases, the CWSS is the sequence 
LPXTG.1,5 Using previously published numbering 
(L=P4, P=P3, X=P2, T=P1, and G=P1’), P4, P3 
and/or P1’ of this motif vary amongst different 
classes.5 Following target recognition, a His-Cys-
Arg catalytic triad facilitates a transpeptidation 
reaction whereby the CWSS is first cleaved between 
the P1 and P1’ residues via nucleophilic attack by the 
catalytic Cys, resulting in a thioester linkage with the 
P1 position of the CWSS. Resolution of this acyl-
enzyme intermediate is then achieved by 
nucleophilic attack by an amino group displayed on 
the cell wall building block lipid II, or in the case of 
pilus formation, displayed on a separate protein 
subunit.1,3,5,6 The final result is formation of a new 
amide linkage, with the portion of the substrate N-
terminal to the CWSS now covalently attached at its 
C-terminus to the amine nucleophile ligation partner. 
The ability to cleave a substrate sequence and 
subsequently ligate a second component (for 
example a protein or synthetic peptide derivative) 
make sortases an attractive tool for protein 
Figure 1. The sortase-fold is conserved in all classes of bacterial 
sortases. (A) The peptide-bound structure of S. aureus SrtA 
(saSrtA) is shown in cartoon representation, with b-strands colored 
and labeled (PDB ID: 2KID) 17. The side chains of the catalytic 
residues (H120, C184, and R197) are shown as sticks, colored by 
heteroatom (O=red, N=blue, S=yellow), and labeled. The disulfide 
-linked peptide analog, Cbz-LPAT*, where Cbz is a 
carbobenzyloxy protecting group and T* is (2R,3S)-3-amino-4-
mercapto-2-butanol, is shown as black sticks and colored by 
heteroatom 17. A zoomed-in version of the active site is shown in 
the black box, with features indicated as in (A). The variable loops 
are labeled and indicated by gray arrows. (B) The overall sortase-
fold is well conserved in proteins of different classes. Here, 
structures for Class B (PDB ID 1NG5), Class C (3O0P), Class D 
(2LN7), Class E (5CUW), and Class F (5UUS) sortases are in 
cartoon, with conserved b-strands colored as in (A), highlighting 
the 8-stranded sortase-fold. The conserved catalytic triad is shown 




engineering efforts, commonly called sortase-mediated ligation (SML) or sortagging.3 Sortase A from 
Staphylococcus aureus (saSrtA) was the first of these enzymes discovered and continues to see widespread use 
for in vitro SML experiments.1,7 Recent years have seen notable improvements in SML technology, including 
strategies for limiting the reversibility of the ligation reaction, and the development of saSrtA variants with 
dramatically improved catalytic efficiency.3,8,9 However, as a consequence of the narrow substrate selectivity of 
saSrtA10, the majority of SML examples rely on the combination of one ligation partner displaying an LPXTG 
motif near its C-terminus with another possessing one or more N-terminal glycines. This restricted substrate scope 
can be advantageous, for example in the use of SML for labeling specific polypeptides in complex mixtures, but 
it also represents a limitation for certain applications (PMID: 33290621).11,12 Highlighting this point, an 
increasing number of studies have demonstrated that the use of naturally occurring sortases or engineered sortases 
with altered substrate selectivity offer distinct advantages such as reducing the necessity for point mutations in 
protein semisynthesis applications12, enabling the labeling of endogenous proteins that do not naturally contain 
the LPXTG motif11,13, and allowing labeling of multiple sites within the same protein target.11,14 Thus, the 
engineering and discovery of sortases with altered substrate profiles, along with a better understanding of the 
biochemical basis for sortase substrate selectivity, represent important areas for the continued development of 
SML technology. 
With respect to substrate recognition, previous mutagenesis and structural studies of various sortases 
provide a wealth of knowledge about initial ligand recognition and subsequent cleavage (thioesterification), as 
well as nucleophile recognition and mechanistic details of peptide ligation (transpeptidation).1,2,10 Specifically, 
the catalytic residues of all native sortases identified to date are (using saSrtA numbering unless specified 
otherwise): His120 (general acid/base), Cys184 (nucleophile, acyl-enzyme intermediate), and Arg197 (transition 
state stabilization) (Figure 1A).1,10 Additionally, directed evolution studies have identified mutations 
(P94R/D160N/D165A/K190E/K196T) that are together able to boost the catalytic efficiency of saSrtA by 120-
fold.8 Of these 5 mutations, several are located in two of the three structurally conserved loops in Class A sortases 
located near the peptide-binding cleft: those between the b4, b5 strands (b4-b5 loop), the b6, b7 strands (b6-b7 
loop, where D165A occurs), and the b7, b8 strands (b7-b8 loop, where K190E and K196T are located). Notably, 
while the increase in enzyme activity afforded by these mutations included a 3.6-fold increase in kcat, the effect 
was dominated by a 33-fold decrease in KM, suggesting these loop residues may be important in CWSS 
recognition.8 
Additional evidence for the role of loop residues has been obtained from more targeted directed evolution 
and mutagenesis studies. For example, it has been demonstrated that the b6-b7 loop of saSrtA directly confers 
specificity at P4 of the recognition motif (LPXTG), and residues other than leucine (L) can be accommodated 
using sortases with mutations in the b6-b7 loop.11,12,15 Indeed, substitution of the b6-b7 loop residues from saSrtB 
into the saSrtA enzyme alters substrate recognition to that of a sortase B protein (NPQTN).16 Turning to the b7-
b8 loop, the NMR structure of saSrtA covalently bound to a modified LPAT* peptide mimetic revealed a 
non-covalent interaction between W194 in saSrtA and the Thr residue in P1 (LPXTG).17,18 Mutation of W194 in 
saSrtA decreased the reaction rate, although it was not essential to catalysis.18 Taken together, these past studies 
reveal that sequence variation within sortase loops directly affects both activity and selectivity for target ligands. 
Furthermore, conservation of the closed eight-stranded b-barrel core in all sortase A-F structures that have been 
reported to date suggests that these principles may apply to non-Class A sortases as well (Figure 1B).2 
The published structure of S. pneumoniae SrtA (spSrtA, 
PDB ID: 4O8L) is of a domain swap dimer. In its dimer form, 
spSrtA is inactive thus its structure does not give insight to the 
active conformation of Class A sortases. Looking in the Protein 
Database, we found Streptococcus agalaticae (sagSrtA, PDB 
ID: 3RCC) crystallized as a dodecamer with six monomeric 
units forming a ring and two rings stacked together. With the 
knowledge that sagSrtA has previously been crystallized, it 
forms the basis for our structural investigation of chimeric 
sagSrtA variants and co-crystallization structures of the 
LPATXG substrate with sagSrtA. 





Loop-swapped b7-b8 chimeric enzymes selectivity for P1’ 
Previous research in the lab has shown that the 
broaden substrate scope can be attributed to the role 
that b7-b8 loop playing a key role in the differing 
substrate preferences.19 Moreover, variations in 
b7-b8 loop sequences can substantially impact 
overall enzyme activity, affording chimeric sortases 
that outperform their wild-type counterpart in vitro.19 
Using the full-length sequence of SrtA in 
Streptococcus agalaticae as the base, four chimeric 
enzymes were created using previous tested b7-b8 
loops to confirm trends seen before. These chimeras 
include b7-b8 loop residues from Staphylococcus 
aureus (sagSrtAaureus), Enterococcus faecalis 
(sagSrtAfaecalis), Listeria monocytogenes 
(sagSrtAmonocytogenes), and Streptococcus pneumoniae 
(sagSrtApneumoniae) (Figure 2). Enzymatic assays were 
preformed using LPATGG, LPATAG, and LPATSG 
substrates to obtain the relative activity.  
  
Within the 2 hr time frame of our assay, wild-
type sagSrtA is more promiscuous then saSrtA, able 
to react with all three substrates. This promiscuity is 
similar to spSrtA with a key difference in that sagSrtA cleaves LPATAG two-times more efficiently. When the 
S. aureus b7-b8 loop is swapped in, we see that sagSrtAaureus mimics saSrtA’s selectivity for the glycine in the 
P1’ position with an efficiency that is one-fifth of saSrtA. sagSrtAfaecalis has 
an increase in efficiency with all three substrates, predominantly in the A- and 
G-containing peptides. The sagSrtAmonocytogenes fundamentally mimics saSrtA 
being selective only for the G-containing peptide but is seen to have even less 
efficiency than sagSrtAaureus. Finally, sagSrtApneumoniae shows similar 
efficiency and promiscuity to spSrtA for all peptides except for the S-
containing, being only half as efficient (Figure 3). All chimeric enzymes 
followed promiscuity and selectivity trends seen when similar chimeric 
enzymes were created using the Streptococcus pneumonia SrtA as the base 
structure.19 
 
Full-Length Structure of Streptococcus agalaticae SrtA 
 
 The published structure of sagSrtA is of a truncated version of the 
enzyme, which removes the last nine residues from the C-terminus tail.20 
The effects on activity due to this truncation was investigated via 
fluorescence assays and revealed that sagSrtAtrunc is inactive for all three 
substrates (Table 1). C-terminal tail is important in the enzymes structure 
and its ability to cleave and ligate. To investigate this difference, we 
expressed, purified, crystallized and solved the structure of full length 
sagSrtA to a high resolution of 1.4 Å. Structural alignment of sagSrtAtrunc 
(PDB ID: 3RCC) to full-length sagSrtA showed significant deviations 
between the structures with an RMSD of 0.857 Å over 711 main chain 
atoms. The b6-b7 and b7-b8 loops, both important in substrate recognition 
A B 
Figure 3. (A) Substrate selectivity profiles for saSrtA and spSrtA. 
(B) Substrate selectivity profiles for wild-type sagSrtA and 
chimeric sagSrtA variants. Substrate cleavage monitored via an 
increase in fluorescence at 420 nm from reactions of fluorophore-
quencher probes with the generic structure Abz-LPATXG-K(Dnp) 
(LPATX) in the presence of hydroxylamine. Bar graphs represent 
mean normalized fluorescence (± standard deviation) from at least 
three independent experiments.   
Figure 4. Structural alignment of 
sagSrtAtrunc (pink) and full-length 
sagSrtA (aqua). 
Table 1. Substrate selectivity 
profiles for saSrtA, sagSrtA, 
sagSrtAtrunc and spySrtA. 
 
 
and cleavage, showed the greatest amounts of movement compared to other regions (Figure 4). This difference 
in structure we hypothesize is due to the non-endogenous dodecameric interactions that the sagSrtAtrunc enzyme 
was crystallized in causing shifts in structure to pack into the oligomeric form.  
 
Streptococcus agalaticae swap aureus SrtA Structure 
 
  Upon obtaining the full length sagSrtA structure, we went on to 
crystallize the chimeric loop swaps that we had created for enzymatic assays. 
We were only able to crystallize the sagSrtAaureus even though the other loops 
are of more similar lengths than the S. aureus b7-b8 loop. While solving the 
structure we realized that the loop sequences was actually incorrect as the 
asparagine was omitted (Figure 2, 5). This enzyme was also used in the 
enzymatic assays and will need to be redone with the correct loop sequence. 
This mistake did tell us that by removing the asparagine from the loop, it 
does not affect the selectivity of sagSrtA. It still followed the same trend that 





With a full-length structure obtained, we went on 
to co-crystallize sagSrtA with our three substrates. To do 
so, the enzyme is first inactivated by mutating the 
catalytic cystine in position 206 to an alanine via site-
directed mutagenesis. With the correct plasmid in hand, 
the inactive enzyme was expressed, purified and 
crystalized. G-, S- and A-containing peptides were added 
to a final concentration of 1 mM and incubated for an hour 
at room temperature prior to crystallization. The 
LPATGG peptide contains a fluorescein fluorophore 
producing yellow crystals that confirmed peptide and 
protein interaction. Crystals looped from these co-
crystallization setups have been sent to the ALS for data collection and currently structures are being solved.  
 
 Preliminary strucutral analysis using Streptococcus pyogenes SrtA (spySrtA) bound to LPATAG shows a 
high structural alignment with an RMSD of 0.492 Å over 855 main chain atoms. Looking specifically at the loops 
involved in substrate recogntion and selectivity, we see minimal movement in the b6-b7 and b7-b8 loops with 
the greatest deviations between the structures in the b4-b5 loop. Enzymatic assays of spySrtA indicate a three-
fold increase in activity for glycine and serine in the P1’ position while a 2-fold increase for the alanine compared 
to sagSrtA (Table 1). Examining the b7-b8 loop sequence, there is only a one residue difference between the 
two. The third residue following the catalytic cystine in sagSrtA is a proline while in spySrtA is an isoleucine 
(Figure 6). The rigidity of proline effects the flexibility of the loop thus causing the decrease in activity seen in 
sagSrtA.  
 
Looking more closely at LPATAG’s interaction with sagSrtA, the leucine in position P4 fits nicely into a 
hydrophobic pocket. This pocket most likely would not be able to accommodate large hydrophobic residues due 
to the size of the cavity (Figure 7A). The P1’ position of the peptide falls in a hydrophobic ridge which is also 
restrictive of large hydrophobic residues (Figure 7B). The S-containing peptide is accommodated in this ridge as 
the hydroxyl group is able to point out of the pocket. Finally, there are multiple hydrogen bonds made between 
Figure 6. (A) Structural alignment of sagSrtA and spySrtA. 
(B) Zoomed in b7-b8 loop.  
Figure 5. Structural alignment of 
sagSrtA (aqua) and sagSrtAaureus 
(purple). RMSD of 0.485 Å over 867 
main chain atoms. 
 
 
sagSrtA and positions P1, P2 and P3 of the peptide, 
specifically with the catalytic arginine and the backbone of 
the peptide (Figure 7C).  
Conclusion 
Target sequence recognition for Class A sortases is 
not all rigidly selective like S. aureus SrtA for a P1’ glycine 
but it seen to be able to accommodate many residues.14,21–23 
Building off previous work in the lab, we look to understand 
the fundamentals of sortase substate recognition through 
structural analysis. S. agalaticae SrtA as the launching off 
point of these studies due to a published structure. From our 
studies, we also solved the first full-length structure of 
sagSrtA and discovered that the published structure was a 
crystal artifact. We also solved the structure of a chimeric 
variant, sagSrtAaureus, but due to a wrong loop sequence, our 
finding cannot be confirmed just yet but the asparagine that 
was omitted does not seem to be a key residue in substrate 
recognition. sagSrtA aligned to a high degree to spySrtA 
allowing for preliminary structural analysis of peptide bound 
structure. Similar to spySrtA, sagSrtA also exhibited: (1) a 
hydrophobic pocket that accommodates the P4 position, (2) 
multiple hydrogen bond interactions and (3) a hydrophobic 
ridge limiting the residues compatible in the P1’ position. We 
also found that the proline within the b7-b8 loop sequence 
of sagSrtA greatly hindered its ability to efficiently cleave its substrate. This work also has implications for the 
further development of sortase-mediated ligation (SML) as a protein engineering tool.3,24 
The development of these new sortase/substrate pairs has exciting consequences for SML engineering 
efforts: (1) it increases options for dual-labeling single proteins or multiplexed labeling of multiple proteins in the 
same systems25–27, and (2) it may reduce the need to mutate naturally occurring protein sequences in order to 
render their termini compatible with SML. Developing a deeper understanding of how residues in these loops 
affect substrate selectivity in all sortase classes may enable dramatic expansion of the sortase “toolbox”, 
potentially allowing the development of ligases that are tailored to the needs of specific protein targets while also 
limiting off-target effects.  
Experimental Procedures (adapted from Gao et al. and Piper et al.) 
Protein expression and purification. Wild-type spSrtA and saSrtA proteins were expressed and purified as 
previously described.28 All other constructs, including chimeric and mutant proteins, were purchased from 
Genscript in the pET28a(+) vector. In general, protein expression and purification protocols were very similar to 
those previously described.28 Briefly, plasmids were transformed into Escherichia coli BL21 (DE3) competent 
cells and grown in LB media, with protein induction at OD600 0.6-0.8 using 0.15 M IPTG for 18-20 h at 18°C.   
Following cell harvest in lysis buffer [0.05 M Tris pH 7.5, 0.15 M NaCl, 0.0005 M 
ethylenediaminetetraacetic acid (EDTA)], the protein was purified using a 5 mL HisTrap HP column (GE Life 
Sciences, now Cytiva), using wash [0.05 M Tris pH 7.5, 0.15 M NaCl, 0.02 M Imidazole pH 7.5, 0.001 M TCEP] 
and elution [wash buffer, with 0.3 M Imidazole pH 7.5] buffers. Size exclusion chromatography (SEC) was 
conducted using a HiLoad 16/600 Superdex 200 column (GE Life Sciences, now Cytiva) in SEC running buffer 
[0.5 M Tris pH 7.5, 0.15 M NaCl, 0.001 M TCEP]. Purified protein corresponding to the monomeric peak was 
concentrated using an Amicon Ultra-15 Centrifugal Filter Unit (10,000 NWML) and analyzed by SDS-PAGE. 
Protein not immediately used was flash frozen in SEC running buffer and stored at -80°C.  
 
Figure 7. Electrostatic surface of sagSrtA with 
LPATAG. (A) Hydrophobic pocket where leucine sits. 
(B) Hydrophobic ridge that restricts large hydrophobic 
residues.  (C) Hydrogen bonding of sagSrtA with 
peptide backbone and side chain. 
 
 
Peptide synthesis. Detailed synthetic procedures are provided in the Supplemental Data. Briefly, all peptides were 
synthesized via manual Fmoc solid phase peptide synthesis (SPPS). Peptides were synthesized either individually 
or in tandem using Fmoc Rink amide MBHA resin or Synphase lantern solid supports. All other materials, 
including suitably protected Fmoc amino acids, and reagents for coupling, deprotection, and resin cleavage were 
obtained from commercial sources and used without further purification. All peptides were purified using RP-
HPLC and their identities were confirmed via ESI-MS. Prior to use in sortase-catalyzed transacylation reactions, 
each purified peptide was prepared as a concentrated stock solution in DMSO and/or H2O. 
  
Fluorescence Assay for Sortase Activity. Reactions were performed in a Costar round-bottom, black 96-well plate 
at a 100 µL reaction volume under the following conditions: 5 µM sortase, 50 µM peptide substrate, and 5 mM 
hydroxylamine nucleophile. All reactions contained 10% (v/v) 10x sortase reaction buffer (500 mM Tris pH 7.5, 
1500 mM NaCl, and 100 mM CaCl2). Reactions also contained residual DMSO from the peptide stock solutions 
(0.5-1.5% (v/v), with the exception of the Phe- and Val-containing peptides at 5%). The peptides containing 
phenylalanine or valine required 5% (v/v) DMSO for solubility under the reaction conditions. 1 mM TCEP was 
also included in reactions utilizing the Abz-LPATCG-K(Dnp) substrate. Reactions were initiated by the addition 
of the sortase enzyme, which were prepared as 10x stock solutions in 50 mM Tris pH 7.5, 150 mM NaCl, and 1 
mM TCEP. Microplates were analyzed using a Biotek Synergy H1 plate reader. The fluorescence intensity of 
each well was measured at 2-min time intervals over a 2-hr period at room temperature (lex = 320 nm, lem = 420 
nm, and detector gain = 75). All reactions were performed in triplicate. For each substrate sequence, the 
background fluorescence of the intact peptide in the absence of enzyme was subtracted from the observed 
experimental data. Background-corrected fluorescence data was then normalized to the fluorescence intensity of 
a benchmark reaction between wild-type saSrtA and Abz-LPATGG-K(Dnp). 
 
Crystallization, Data Collection, and Structure Determination. The protein concentrations used for crystallization 
was approximately 15 mg/ml. Peptide was added at a final concentration of 1 mM and incubated with protein for 
1-hour prior to crystallization. All initial crystallization conditions were identified using the PEGRx screen 
(Hampton Research). The crystallization conditions of crystals used for data collection were: sagSrtA [100 mM 
MES monohydrate pH 6.0, 20% (v/v) 2-propanol, 20% (w/v) PEG monomethyl ether 2000] and 
sagSrtA:LPATGG [80-120 mM sodium acetate trihydrate, 26-32% (w/v) PEG 1500].  
For data collection, all co-crystallization crystals grown from lab made well solutions were transferred 
into cryoprotectant buffer made of well solution plus 20% (w/v) glycerol. For full-length sagSrtA, 15% (w/v) 
glycerol was added directly to the respective PEGRx screen solution. The crystals were flash-cooled by plunging 
into liquid nitrogen. Data was collected at the Advanced Light Source (ALS) at the Lawrence Berkeley National 
Laboratory (LBNL) on beamline 5.0.1, at l=0.977410 Å over 360°, with Df=0.25° frames and an exposure time 
of 0.5 s per frame. Molecular replacement was performed using Phenix with the following search model: sagSrtA 
(PDB ID: 3FN5, spySrtA). Refinement was performed using Phenix, manual refinement was done using Coot, 
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